Marco Metra, MD is an expert in Cardiology at Spedali Civili di Brescia (Italy). As of October 2026, ScienceLeadR ranks Marco Metra in the top 1% of experts worldwide for Heart Failure, Mitral Valve Insufficiency and Cardiomyopathies. Marco Metra has authored 1,743 publications, the most recent in 2026, and is an investigator in 61 clinical trials, 7 of them ongoing. SLR score: 6,768 (community average: 125). How the SLR is computed.

LeadR Profile

Marco Metra, MD Spedali Civili di Brescia Italy
6 768 ScienceLeadR Reputation 6768
Network Map

Cardiology

Subspecialties: Public Health - Biostatistics - Internal Medicine

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

Marco Metra, MD

Full Professor of Cardiology

Cardiology. IRCCS San Raffaele Scientific institute. Milan

Vita-Salute San Raffaele University. Milan. Italy

Marco Metra is Full professor of cardiology at the Vita-Salute San Raffaele University and directs the Clinical Cardiology and Invasive Cardiology Unit of the IRCCS San Raffaele Scientific Institute of Milan, Italy. He was former Director of the Institute of Cardiology of the Civil Hospital and University of Brescia, Italy, since November 2012 and Full Professor of Cardiology at the University of Brescia, Italy, since December 2015. He was Editor-in-Chief of the European Journal of Heart Failure, from November 2015 to April 2021. He is Editor-in-Chief European Heart Journal – Valvular and Structural Heart Disease since August 2025. He is President of the Heart Failure Association of the European Society of Cardiology since April 2024.

Marco Metra received his medical degree in 1981 and then received the post-graduate fellowships in Internal Medicine and in Cardiology, at the University of Parma. He was a research associate at the Committee on Clinical Pharmacology of the University of Chicago, Illinois, (Director, Prof. Leon I. Goldberg), in 1985, returning to work at the Cardiology Institute of the University of Brescia in 1986. He was appointed Associate Professor of Cardiology in 2001 and then became Full Professor of Cardiology in 2015 at the University of Brescia.

Prof. Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with heart failure. He is co-chair of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2023 ESC HF guidelines update

Prof Metra served as board member of the HFA of ESC from 2001 to 2008, being secretary of the executive board from 2004 to 2006 and then served as ex-officio member of the HFA board from 2015 and then as President elect since 2022. He has also been a member of the ESC’s Committee for Practice Guidelines in the years 2004 to 2008, member of the ESC Congress Program Committee in the years 2008-2012 and 2023.

He is author of more than 1700 articles in peer-reviewed journals, current scopus H-index, 129, google scholar H index, 143, ranking 48 in the Top Italian Scientists Biomedical Sciences rank https://topitalianscientists.org/TIS_HTML/Top_Italian_Scientists_Biomedical_Sciences.htm

Organizations

Career arc: 1988 - 2026

Source: PubMed

Vita-Salute San Raffaele University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1743

Citations

Citations: 122 520 1st author: 115 Last author: 309 Unique author: 59


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Management of Heart transplant recipients for the non Heart Transplant health care provider. A Clinical Consensus Statement of the Heart Failure Association (HFA) and the Association of Cardiovascular Nursing & Allied Professions (ACNAP) of the ESC.
PMID 42895118 — heart failure, heart, nursing, cardiovascular nursing, health personnel, occupations, transplants, therapeutics, immunosuppression therapy, transplantation
Eur J Heart Fail20260
Prognostic Impact of Moderate Secondary Mitral Regurgitation After Optimized Medical Therapy in Heart Failure.
PMID 42888505 — mortality, incidence, heart failure, heart, echocardiography, therapeutics, mitral valve insufficiency, prognosis
ESC Heart Fail20260
Prevalence and prognostic role of left atrial reverse remodeling in patients undergoing mitral transcatheter edge-to-edge repair: insights from the Multicenter Echocardiographic Registry of patients undergoing mitral Transcatheter Edge-to-Edge Repair.
PMID 42886843 — registries, mortality, hospitalization, heart failure, heart, cardiovascular diseases, prevalence, mitral valve insufficiency
J Cardiovasc Med (Hagerstown)20260
"Baseline Characteristics and Utilization of Medical Therapies in Acute Hospitalized and Chronic Heart Failure Patients Enrolled in GRASP-HF: Differences Between ICARe-HF and Non-ICARe-HF Centres".
PMID 42867408 — mortality, heart failure, heart, hospital mortality, heart failure, systolic, therapeutics
Eur J Heart Fail20260
GDMT is Associated with Reduced Loop Diuretic Requirements, Whereas Diuretic Dose Does Not Modify GDMT Benefit in Heart Failure: STRONG-HF.
PMID 42852467 — heart failure, heart, diuretics, therapeutics, furosemide, prognosis
Eur J Heart Fail20260

Clinical Studies 61

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 3 28
N/A 14
Phase 2 11
Phase 2/Phase 3 3
Phase 4 3
Phase 1/Phase 2 2

By status:

Completed 43
Recruiting 6
Terminated 4
Unknown 4
Active not recruiting 2
Enrolling by invitation 1
Not yet recruiting 1

By type:

Interventional 50
Observational 11

By Monocentric/Multicentric:

monocentric 13
multicentric2to4 2
multicentric5to9 1
multicentricup10 45

Main Topics

Cohort/Consortium Investigators 5

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
HF POLARIS A research study to look at how well NNC0487 0111 works compared to placebo in people with heart failure and obesity
2025-523717-29-00 — mortality, safety, heart failure, heart, heart failure, diastolic, obesity, morbidity, research
Phase 3Recruiting2026
Bempedoic acid ezetimibe high intensity statin in patients without cardiovascular events
2025-524625-41-00 — ezetimibe, atherosclerosis, hydroxymethylglutaryl-coa reductase inhibitors
Phase 3Not yet recruiting2026
Metabolic Exercise Test Data Combined with Cardiac and Kidney Indexes (MECKI) Score Evolution Identification of Cardiovascular Risk in Patients with Heart Failure
NCT06884631 — exercise, heart failure, exercise test, heart, kidney, therapeutics, prognosis
N/ARecruiting2021
European Registry of Transcatheter Repair for Tricuspid Regurgitation
NCT06307262 — registries, heart valve diseases, heart diseases, heart failure, heart, tricuspid valve, tricuspid valve insufficiency, heart valves
N/ARecruiting2023
A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non Obstructive Hypertrophic Cardiomyopathy (nHCM)
NCT06081894 — safety, multiple chronic conditions, tablets, cardiomyopathy, hypertrophic, cardiomyopathies
Phase 3Active not recruiting2023

LeadR Networks

Main global connection map